tirzepatide and kidney issues (Zepbound) showed improved function in obese patients with both chronic kidney disease #heartfailure with preserved ejection fraction, highlighting its potential to address this high-risk patient population. Read more: https Tirzepatide reduces kidney damage and

Payer-Specific Rules for CPT 96372: BCBS, UnitedHealthcare, and Medicare Rules vary by payer

The SURMOUNT trials demonstrated average weight loss of 22.5% at this level, with 63% of participants losing at least 20% of their body weight

Achieve up to 20% body weight reduction with Wegovy and you may also see improvements in the following: In the STEP 1 trial, people using Wegovy saw greater reductions in systolic blood pressure compared to those on placebo with an average drop of 6.2 mmHg vs 1.1 mmHg. Treatment with Wegovy led to greater improvements in cholesterol measures, including reductions in total cholesterol, LDL ("bad" cholesterol), and triglycerides. By supporting weight loss and improving key health markers including waist circumference with a 5.7-inch (14.5cm) reduction vs 2-inch (5cm) reduction with placebo

This means doing more physical activity and changing their diet, along with using tirzepatide, to get better health outcomes related to heart failure

The SOUL Trial (Oral Semaglutide): McGuire DK, et al